Cancer research laboratory workspace.
Cancer research laboratory workspace.

Cancer research has led to a greater understanding of the interactions between cancer cells and the immune system, paving the way for the development of immuno-oncology. This field of study focuses on how the body’s natural defenses can be used or modified to recognize and target cancer cells. Immuno-oncology approaches differ from conventional anticancer agents like chemotherapy and radiation, as they interact with different components of the immune system.

Immune checkpoint inhibitors, cancer treatments using genetically modified cells, and therapeutic cancer vaccines are some of the approaches being investigated. Pharmaceutical companies, biotechnology organizations, and universities are conducting research in laboratories around the world to explore these approaches, both as single agents and in combination with conventional treatments.

Understanding the Science Behind Immuno-Oncology

An individual’s immune system is composed of several cells, proteins, and signaling pathways that defend against foreign substances. The immune system can sometimes recognize and destroy abnormal cells that could develop into cancer. However, some cancer cells can develop ways to hide from the immune system or prevent it from functioning properly.

For example, some cancer cells can express proteins that inhibit the function of T-cells. Research into the ways tumors evade immune recognition and how their immune evasion mechanisms can be addressed is a key area of focus in immuno-oncology. The National Cancer Institute (NCI) defines immunotherapy as a variety of approaches that help the immune system kill cancer cells.

Each of these approaches is based on different biological principles.

Immune Checkpoint Inhibitors and CAR-T Cell Therapy

Immune checkpoint inhibitors target signaling pathways that normally regulate immune responses, helping to support T-cell activity. Some of these drugs are already approved for certain types of cancer and are being studied in other types of cancer as well. CAR-T cell therapy, on the other hand, involves modifying a patient’s own T-cells to recognize a specific antigen expressed by cancer cells.

While there are many studies on the use of CAR-T cells in blood cancers, additional approaches are being explored for use in solid tumors. Challenges in this type of therapy include the tumor microenvironment and the cancer’s ability to suppress immune responses. Researchers are working to better understand how naturally occurring tumor-reactive cells can be used in cancer treatment.

Biomarkers can supply information about the molecular and biological characteristics of cancer, helping to identify patients who may be eligible for certain immunotherapy approaches. For example, PD-L1 expression on cancer cells and other tumor characteristics can help guide treatment decisions.

However, the presence of a biomarker does not necessarily mean that patients will experience clinical benefit from a particular immunotherapy. Further research is needed to fully understand the role of biomarkers in immuno-oncology and how they can be used to improve treatment outcomes. The US Food and Drug Administration (FDA) Oncology Center of Excellence is conducting scientific and regulatory work in immuno-oncology, including activities related to clinical trial approaches and the development of new immune-based therapeutic agents.

Despite these challenges, researchers remain committed to advancing the field of immuno-oncology and exploring new approaches to cancer treatment.

Regulatory bodies, such as the FDA, play a critical role in evaluating investigational therapies and ensuring their safety and efficacy. The development of investigational immuno-oncology therapies involves multidisciplinary collaboration among pharmaceutical developers, biotechnology researchers, hospitals, academic institutions, and contract research organizations worldwide.

As the field of immuno-oncology continues to evolve, it’s likely that new and innovative approaches to cancer treatment will emerge. With ongoing research and development, there is hope that immuno-oncology will become an increasingly important part of cancer treatment, offering new options for patients and improving outcomes. The National Cancer Institute is one organization that is working to advance our understanding of cancer and develop new treatments, including those related to immuno-oncology.